ATORVASTATIN 80MG CM REC 1000022038

This tender concerns the supply of Atorvastatin 80mg, identified by the reference number 1000022038. Atorvastatin is a widely used medication belonging to the statin class, primarily prescribed to lower cholesterol levels in the blood. High cholesterol is a significant risk factor for cardiovascular diseases, including heart attacks and strokes. By inhibiting HMG-CoA reductase, the enzyme responsible for cholesterol synthesis in the liver, Atorvastatin effectively reduces levels of low-density lipoprotein (LDL) cholesterol, often referred to as 'bad' cholesterol, while potentially increasing high-density lipoprotein (HDL) cholesterol, or 'good' cholesterol. The tender is likely issued by a healthcare provider, a government health agency, or a pharmaceutical procurement body responsible for ensuring the availability of essential medicines. The specific quantity and delivery timelines will be detailed in the full tender documentation. Bidders are expected to meet stringent quality standards and regulatory requirements for pharmaceutical products. This procurement aims to secure a reliable supply of this critical medication to meet patient needs within the specified healthcare system. Further details regarding the bidding process, eligibility criteria, and submission deadlines are available in the official tender announcement.

This is a services contract in the health and medical services, trade and industry and general supplies sectors. Located in Chile, Latin America, this opportunity is open to firms and consortiums.

Published through Chile Mercado Publico, a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for services in the health and medical services sector. Service contracts are typically evaluated on both technical quality and price, and may require bidders to demonstrate relevant experience and qualified personnel. This contract has already been awarded. The information is published for transparency and market intelligence purposes.